Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Long-Term Deferred Tax (2019 - 2024)

Eton Pharmaceuticals' Long-Term Deferred Tax history spans 2 years, with the latest figure at $18.5 million for Q4 2021.

  • For Q4 2021, Long-Term Deferred Tax changed N/A year-over-year to $18.5 million; the TTM value through Dec 2021 reached $18.5 million, changed N/A, while the annual FY2021 figure was $18.5 million, N/A changed from the prior year.
  • Long-Term Deferred Tax for Q4 2021 was $18.5 million at Eton Pharmaceuticals, up from $9.7 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $18.5 million in Q4 2021 and bottomed at $9.7 million in Q4 2019.